223 related articles for article (PubMed ID: 20493430)
1. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
[TBL] [Abstract][Full Text] [Related]
2. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
3. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R
J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878
[TBL] [Abstract][Full Text] [Related]
4. Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan.
Wago T; Yoshimoto T; Akaza I; Tsuchiya K; Izumiyama H; Doi M; Hirata Y
Hypertens Res; 2010 Aug; 33(8):796-801. PubMed ID: 20555330
[TBL] [Abstract][Full Text] [Related]
5. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro.
Yamada S; Ano N; Toda K; Kitaoka A; Shiono K; Inoue G; Atsuda K; Irie J
Hypertens Res; 2008 Apr; 31(4):601-6. PubMed ID: 18633170
[TBL] [Abstract][Full Text] [Related]
6. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study.
Lee IT; Hung YJ; Chen JF; Wang CY; Lee WJ; Sheu WH
Clin Ther; 2012 Aug; 34(8):1735-50. PubMed ID: 22784975
[TBL] [Abstract][Full Text] [Related]
8. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
Nixon RM; Müller E; Lowy A; Falvey H
Int J Clin Pract; 2009 May; 63(5):766-75. PubMed ID: 19392925
[TBL] [Abstract][Full Text] [Related]
9. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
Miura Y; Yamamoto N; Tsunekawa S; Taguchi S; Eguchi Y; Ozaki N; Oiso Y
Diabetes Care; 2005 Mar; 28(3):757-8. PubMed ID: 15735228
[No Abstract] [Full Text] [Related]
10. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance.
Makita S; Abiko A; Naganuma Y; Moriai Y; Nakamura M
Metabolism; 2008 Oct; 57(10):1473-8. PubMed ID: 18803955
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of combination therapy using high- or low-dose hydrochlorothiazide with valsartan or other Angiotensin-receptor blockers.
Fuenfstueck R; Hempel RD; Ansari A; Weidinger G; Klebs S
Adv Ther; 2005; 22(3):263-77. PubMed ID: 16236687
[TBL] [Abstract][Full Text] [Related]
12. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes.
Mori Y; Itoh Y; Tajima N
Adv Ther; 2007; 24(1):146-53. PubMed ID: 17526471
[TBL] [Abstract][Full Text] [Related]
13. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
White WB; Murwin D; Chrysant SG; Koval SE; Davidai G; Guthrie R
Blood Press Monit; 2008 Feb; 13(1):21-7. PubMed ID: 18199920
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension.
Arao T; Okada Y; Mori H; Nishida K; Tanaka Y
Endocr J; 2013; 60(5):563-70. PubMed ID: 23303198
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients.
Mori H; Okada Y; Arao T; Nishida K; Tanaka Y
Adv Ther; 2012 Jul; 29(7):635-44. PubMed ID: 22821644
[TBL] [Abstract][Full Text] [Related]
16. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
White WB; Lacourciere Y; Davidai G
Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
[TBL] [Abstract][Full Text] [Related]
17. Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report.
Suzuki H; Sakamoto M; Hayashi T; Iuchi H; Ohashi K; Isaka T; Sakamoto N; Kayama Y; Tojo K; Yoshimura M; Utsunomiya K
Cardiovasc Diabetol; 2013 May; 12():71. PubMed ID: 23635096
[TBL] [Abstract][Full Text] [Related]
18. Telmisartan or valsartan alone or in combination with hydrochlorothiazide: a review.
Lacourcière Y
Clin Exp Hypertens; 2013; 35(1):50-60. PubMed ID: 22866964
[TBL] [Abstract][Full Text] [Related]
19. Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension.
Bekki H; Yamamoto K; Sone M; Homma T; Nakata M; Nohara M; Fukami K; Okuda S; Yamagishi S
Clin Cardiol; 2011 Apr; 34(4):261-5. PubMed ID: 21432858
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients.
Hong SJ; Choi SC; Ahn CM; Park JH; Kim JS; Lim DS
Heart; 2011 Sep; 97(17):1425-32. PubMed ID: 21700754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
